178 related articles for article (PubMed ID: 33251859)
21. Customizing monoclonal antibodies for the treatment of methamphetamine abuse: current and future applications.
Peterson EC; Gentry WB; Owens SM
Adv Pharmacol; 2014; 69():107-27. PubMed ID: 24484976
[TBL] [Abstract][Full Text] [Related]
22. Development of Methamphetamine Conjugated Vaccine through Hapten Design: In Vitro and In Vivo Characterization.
Hossain MK; Davidson M; Feehan J; Deraos G; Nurgali K; Matsoukas J; Apostolopoulos V
Vaccines (Basel); 2023 Feb; 11(2):. PubMed ID: 36851217
[TBL] [Abstract][Full Text] [Related]
23. Is immunotherapy an opportunity for effective treatment of drug addiction?
Zalewska-Kaszubska J
Vaccine; 2015 Nov; 33(48):6545-51. PubMed ID: 26432911
[TBL] [Abstract][Full Text] [Related]
24. Using hapten design to discover therapeutic monoclonal antibodies for treating methamphetamine abuse.
Peterson EC; Gunnell M; Che Y; Goforth RL; Carroll FI; Henry R; Liu H; Owens SM
J Pharmacol Exp Ther; 2007 Jul; 322(1):30-9. PubMed ID: 17452421
[TBL] [Abstract][Full Text] [Related]
25. Pharmacotherapeutic strategies for methamphetamine use disorder: mind the subgroups.
Soares E; Pereira FC
Expert Opin Pharmacother; 2019 Dec; 20(18):2273-2293. PubMed ID: 31671001
[No Abstract] [Full Text] [Related]
26. Recombinant Adeno-Associated Virus-Mediated Expression of Methamphetamine Antibody Attenuates Methamphetamine-Induced Hyperactivity in Mice.
Chen YH; Wu KJ; Wu KL; Wu KL; Tsai HM; Chen ML; Chen YW; Hsieh W; Lin CM; Wang Y
Sci Rep; 2017 Apr; 7():46301. PubMed ID: 28387350
[TBL] [Abstract][Full Text] [Related]
27. The synthesis of haptens and their use for the development of monoclonal antibodies for treating methamphetamine abuse.
Carroll FI; Abraham P; Gong PK; Pidaparthi RR; Blough BE; Che Y; Hampton A; Gunnell M; Lay JO; Peterson EC; Owens SM
J Med Chem; 2009 Nov; 52(22):7301-9. PubMed ID: 19877685
[TBL] [Abstract][Full Text] [Related]
28. Consequence of Hapten Stereochemistry: An Efficacious Methamphetamine Vaccine.
Olson ME; Sugane T; Zhou B; Janda KD
J Am Chem Soc; 2019 Sep; 141(36):14089-14092. PubMed ID: 31479256
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of the BEAT Meth Intervention for Emergency Department Patients with Methamphetamine Psychosis.
Simpson SA; Wolf C; Loh RM; Camfield K; Rylander M
J Addict Med; 2023 Jan-Feb 01; 17(1):67-73. PubMed ID: 35802766
[TBL] [Abstract][Full Text] [Related]
30. Generation of anti-(+)methamphetamine antibodies is not impeded by (+)methamphetamine administration during active immunization of rats.
Byrnes-Blake KA; Carroll FI; Abraham P; Owens SM
Int Immunopharmacol; 2001 Feb; 1(2):329-38. PubMed ID: 11360933
[TBL] [Abstract][Full Text] [Related]
31. Development and testing of AAV-delivered single-chain variable fragments for the treatment of methamphetamine abuse.
Hay CE; Gonzalez GA; Ewing LE; Reichard EE; Hambuchen MD; Nanaware-Kharade N; Alam S; Bolden CT; Owens SM; Margaritis P; Peterson EC
PLoS One; 2018; 13(6):e0200060. PubMed ID: 29958300
[TBL] [Abstract][Full Text] [Related]
32. The neurobiological mechanisms of physical exercise in methamphetamine addiction.
Morais APD; Pita IR; Fontes-Ribeiro CA; Pereira FC
CNS Neurosci Ther; 2018 Feb; 24(2):85-97. PubMed ID: 29266758
[TBL] [Abstract][Full Text] [Related]
33. First human study of a chimeric anti-methamphetamine monoclonal antibody in healthy volunteers.
Stevens MW; Henry RL; Owens SM; Schutz R; Gentry WB
MAbs; 2014; 6(6):1649-56. PubMed ID: 25484042
[TBL] [Abstract][Full Text] [Related]
34. Microneedle Systems for Vaccine Delivery: the story so far.
Hossain MK; Ahmed T; Bhusal P; Subedi RK; Salahshoori I; Soltani M; Hassanzadeganroudsari M
Expert Rev Vaccines; 2020 Dec; 19(12):1153-1166. PubMed ID: 33427523
[TBL] [Abstract][Full Text] [Related]
35. Monoclonal antibodies as pharmacokinetic antagonists for the treatment of (+)-methamphetamine addiction.
Owens SM; Atchley WT; Hambuchen MD; Peterson EC; Gentry WB
CNS Neurol Disord Drug Targets; 2011 Dec; 10(8):892-8. PubMed ID: 22229314
[TBL] [Abstract][Full Text] [Related]
36. Pharmacological treatments for methamphetamine addiction: current status and future directions.
Ballester J; Valentine G; Sofuoglu M
Expert Rev Clin Pharmacol; 2017 Mar; 10(3):305-314. PubMed ID: 27927042
[TBL] [Abstract][Full Text] [Related]
37. Methamphetamine Vaccines: Improvement through Hapten Design.
Collins KC; Schlosburg JE; Bremer PT; Janda KD
J Med Chem; 2016 Apr; 59(8):3878-85. PubMed ID: 27054372
[TBL] [Abstract][Full Text] [Related]
38. Effective active vaccination against methamphetamine in female rats.
Nguyen JD; Bremer PT; Hwang CS; Vandewater SA; Collins KC; Creehan KM; Janda KD; Taffe MA
Drug Alcohol Depend; 2017 Jun; 175():179-186. PubMed ID: 28437722
[TBL] [Abstract][Full Text] [Related]
39. Current and Emerging Treatments for Methamphetamine Use Disorder.
Moszczynska A
Curr Neuropharmacol; 2021; 19(12):2077-2091. PubMed ID: 34344291
[TBL] [Abstract][Full Text] [Related]
40. Oxytocin-enhanced motivational interviewing group therapy for methamphetamine use disorder in men who have sex with men: study protocol for a randomized controlled trial.
Stauffer CS; Moschetto JM; McKernan SM; Hsiang E; Borsari B; Woolley JD
Trials; 2019 Feb; 20(1):145. PubMed ID: 30791944
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
